Page 125 - Read Online

Kornberg et al. Hepatoma Res 2018;4:60 I http://dx.doi.org/10.20517/2394-5079.2018.86 Page 17 of 19

Dig Dis Sci 2015;60:2832-9.
85. Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME, Florman SS. Ischemia time impacts recurrence of hepatocellular
carcinoma after liver transplantation. Hepatology 2015;61:895-904.
86. Grąt M, Kornasiewicz O, Lewandowski Z, Skalski M, Zieniewicz K, Pączek L, Krawczyk M. The impact of surgical technique on the
results of liver transplantation in patients with hepatocellular carcinoma. Ann Transplant 2013;18:448-59.
87. Orci LA, Berney T, Majno PE, Lacotte S, Oldani G, Morel P, Mentha G, Toso C. Donor characteristics and risk of hepatocellular carcinoma
recurrence after liver transplantation. Br J Surg 2015;102:1250-7.
88. Vodkin I, Kuo A. Extended criteria donors in liver transplantation. Clin Liver Dis 2017;21:289-301.
89. Nemes B, Gámán G, Polak WG, Gelley F, Hara T, Ono S, Baimakhanov Z, Piros L, Eguchi S. Extended-criteria donors in liver
transplantation part II: reviewing the impact of extended-criteriadonors on the complications and outcomes of liver transplantation. Expert
Rev Gastroenterol Hepatol 2016;10:841-59.
90. Vinaixa C, Selzner N, Berenguer M. Fat and liver transplantation: clinical implications. Transpl Int 2018;31:828-37.
91. Tashiro H, Kuroda S, Mikuriya Y, Ohdan H. Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver
on hepatic surgery. Surg Today 2014;44:1611-25.
92. Orci LA, Lacotte S, Oldani G, Slits F, De Vito C, Crowe LA, Rubbia-Brandt L, Vallée JP, Morel P, Toso C. Effect of ischaemic
preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis. Br J Surg 2016;103:417-26.
93. Teng da H, Zhu ZJ, Zheng H, Deng YL, Sun LY, Pan C, Liu YH, Song HL, Shen ZY. Effect of steatosis donor liver transplantation on
hepatocellular carcinoma recurrence: experience at a single institution. Hepatogastroenterology 2012;59:858-62.
94. Lué A, Solanas E, Baptista P, Lorente S, Araiz JJ, Garcia-Gil A, Serrano MT. How important is donor age in liver transplantation? World J
Gastroenterol 2016;22:4966-76.
95. Sharma P, Welch K, Hussain H, Pelletier SJ, Fontana RJ, Marrero J, Merion RM. Incidence and risk factors of hepatocellular carcinoma
recurrence after liver transplantation in the MELD era. Dig Dis Sci 2012;57:806-12.
96. Vagefi PA, Dodge JL, Yao FY, Roberts JP. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation.
Liver Transpl 2015;21:187-94.
97. Ghinolfi D, Lai Q, Pezzati D, De Simone P, Rreka E, Filipponi F. Use of elderly donors in liver transplantation: a paired-match analysis at a
single center. Ann Surg 2018;268:325-31.
98. Pinheiro RS, Waisberg DR, Nacif LS, Rocha-Santos V, Arantes RM, Ducatti L, Martino RB, Lai Q, Andraus W, D’Albuquerque LAC.
Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure? Transl Gastroenterol Hepatol
2017;2:68.
99. Cho Y, Lee JH, Lee DH, Cho EJ, Yu SJ, Yi NJ, Lee KW, Kim YJ, Yoon JH, Suh KS. Comparison of treatment outcome between living
donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget 2017;8:47555-64.
100. Chan SC. Section 2. Small-for-size liver graft and hepatocellular carcinoma recurrence. Transplantation 2014;97 Suppl 8:S7-10.
101. Llovet JM, Pavel M, Rimola J, Diaz MA, Colmenero J, Saavedra-Perez D, Fondevila C, Ayuso C, Fuster J, Ginès P, Bruix J, Garcia-
Valdecasas JC. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan criteria
(Barcelona Clinic Liver Cancer extended criteria). Liver Transpl 2018;24:369-79.
102. Liang W, Wu L, Ling X, Schroder PM, Ju W, Wang D, Shang Y, Kong Y, Guo Z, He X. Living donor liver transplantation versus deceased
donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18:1226-36.
103. Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Living vs. deceased donor liver transplantation for hepatocellular
carcinoma: a systematic review and meta-analysis. Clin Transplant 2013;27:140-7.
104. Kim SH, Moon DB, Kim WJ, Kang WH, Kwon JH, Jwa EK, Cho HD, Ha SM, Chung YK, Lee SG. Preoperative prognostic values of
α-fetoprotein (AFP) and protein induced by Vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for
living donor liver transplantation. Hepatobiliary Surg Nutr 2016;5:461-9.
105. Hu Z, Zhong X, Zhou J, Xiang J, Li Z, Zhang M, Wu J, Jiang W, Zheng S. Smaller grafts do not imply early recurrence in recipients
transplanted for hepatocellular carcinoma: a Chinese experience. Sci Rep 2016;6:26487.
106. Lee EC, Kim SH, Shim JR, Park SJ. Small-for-size grafts increase recurrence of hepatocellular carcinoma in liver transplantation beyond
milan criteria. Liver Transpl 2018;24:35-43.
107. Eren EA, Latchana N, Beal E, Hayes D Jr, Whitson B, Black SM. Donations after circulatory death in liver transplant. Exp Clin Transplant
2016;14:463-70.
108. Sutherland AI, Oniscu GC. Challenges and advances in optimizing liver allografts from donation after circulatory deathdonors. J Nat Sci
Biol Med 2016;7:10-5.
109. Croome KP, Wall W, Chandok N, Beck G, Marotta P, Hernandez-Alejandro R. Inferior survival in liver transplant recipients with
hepatocellular carcinoma receiving donation aftercardiac death liver allografts. Liver Transpl 2013 ;19:1214-23.
110. Croome KP, Lee DD, Burns JM, Musto K, Paz D, Nguyen JH, Perry DK, Harnois DM, Taner CB. The use of donation after cardiac death
allografts does not increase recurrence of hepatocellular carcinoma. Am J Transplant 2015;15:2704-11.
111. Khorsandi SE, Yip VS, Cortes M, Jassem W, Quaglia A, O’Grady J, Heneghan M, Aluvihare V, Agarwal K, Menon K, Vilca-Melendez H,
Prachalias A, Srinivasan P, Suddle A, Rela M, Heaton N. Does donation after cardiac death utilization adversely affect hepatocellular cancer
survival? Transplantation 2016;100:1916-24.
112. Orci LA, Lacotte S, Oldani G, Slits F, De Vito C, Crowe LA, Rubbia-Brandt L, Vallée JP, Morel P, Toso C. Effect of ischaemic
preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis. Br J Surg 2016;103:417-26.
113. Orci LA, Lacotte S, Delaune V, Slits F, Oldani G, Lazarevic V, Rossetti C, Rubbia-Brandt L, Morel P, Toso C. Effects of the gut-liver axis
on ischaemia-mediated hepatocellular carcinoma recurrence in the mouse liver. J Hepatol 2018;68:978-85.
114. Kornberg A, Witt U, Kornberg J, Friess H, Thrum K. Treating ischaemia-reperfusion injury with prostaglandin E1 reduces the risk of early
hepatocellular carcinoma recurrence following liver transplantation. Aliment Pharmacol Ther 2015;42:1101-10.